Preventive Effect of Edaravone Ointment on Cyclophosphamide-chemotherapy Induced Alopecia

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2021 Apr 2

PMID 33797584

Citations 8

Authors

Katsuaki Yoneda

Miyu Fujii

Aoi Imaoka

Remi Kobayashi

Ryoya Hayashi

Yuya Yoshida

Takeyuki Kohno

Takumi Tsuji

Affiliations

Soon will be listed here.

Abstract

Purpose: We evaluated the preventive effect of the antioxidant edaravone (EDR) on chemotherapy-induced alopecia (CIA) to improve quality of life in cancer patients.

Methods: Hair loss was induced by intraperitoneally administering cyclophosphamide (CPA, 75 mg/kg) to rats, and topically applying EDR ointment (100 mg/day) once daily for 16 days (when hair loss starts) or 21 days (just before hair growth). The rats were divided into four groups: control group (without CPA or EDR), EDR 0% group (CPA + EDR 0%), EDR 3% group (CPA + EDR 3%), and EDR 30% group (CPA + EDR 30%). The prevention of CIA was evaluated by the hair coverage score (five levels from 0 to 4). Furthermore, we measured the size of the hair follicle area and the expression levels of insulin-like growth factor (IGF)-1 mRNA in dermal papilla cells.

Results: The EDR 3% and EDR 30% groups exhibited higher hair coverage scores than the EDR 0% group on day 16 and day 21. On day 16, the hair follicle area in the EDR 3% and EDR 30% groups was significantly larger than that in the EDR 0% group. Furthermore, IGF-1 expression levels in the EDR 3% group were significantly higher than those in the EDR 0% group. On day 21, no significant difference was observed in hair follicle area or IGF-1 mRNA levels among the groups.

Conclusion: Our results show that EDR administration lessened hair loss due to CPA in a dose-independent manner above doses of 3%, suggesting potential applications beside chemotherapy.

Citing Articles

Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention.

Perez A, Haberland N, Miteva M, Wikramanayake T Curr Oncol. 2024; 31(9):5709-5721.

PMID: 39330051 PMC: 11431623. DOI: 10.3390/curroncol31090423.

Preventive effect of free radical scavenger edaravone lotion on cyclophosphamide chemotherapy-induced alopecia.

Tsuji T, Yoneda K, Igawa Y, Minamino E, Otani N, Yoshida Y Cancer Chemother Pharmacol. 2024; 94(3):467-473.

PMID: 38642149 DOI: 10.1007/s00280-024-04669-1.

Effect of N-acetylcysteine on hair follicle changes in mouse model of cyclophosphamide-induced alopecia: histological and biochemical study.

Hassan Y, Shabaan D Histochem Cell Biol. 2024; 161(6):477-491.

PMID: 38641701 PMC: 11162382. DOI: 10.1007/s00418-024-02282-0.

Edaravone: A Novel Possible Drug for Cancer Treatment?.

Duranti E, Cordani N, Villa C Int J Mol Sci. 2024; 25(3).

PMID: 38338912 PMC: 10855093. DOI: 10.3390/ijms25031633.

Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?.

Wikramanayake T, Haberland N, Akhundlu A, Laboy Nieves A, Miteva M Curr Oncol. 2023; 30(4):3609-3626.

PMID: 37185388 PMC: 10137043. DOI: 10.3390/curroncol30040275.

References

Hesketh P, Batchelor D, Golant M, Lyman G, Rhodes N, Yardley D . Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer. 2004; 12(8):543-9. DOI: 10.1007/s00520-003-0562-5. View

Lemieux J, Maunsell E, Provencher L . Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology. 2007; 17(4):317-28. DOI: 10.1002/pon.1245. View

Komen M, Smorenburg C, Van Den Hurk C, Nortier J . Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist. 2013; 18(7):885-91. PMC: 3720643. DOI: 10.1634/theoncologist.2012-0332. View

Singh K, Bhori M, Kasu Y, Bhat G, Marar T . Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity - Exploring the armoury of obscurity. Saudi Pharm J. 2018; 26(2):177-190. PMC: 6111235. DOI: 10.1016/j.jsps.2017.12.013. View

Sato T, Mizuno K, Ishii F . In vitro metabolism study of edaravone in Wistar and hairless rat skin. Biol Pharm Bull. 2008; 31(6):1150-4. DOI: 10.1248/bpb.31.1150. View

Stenn K, Paus R . Controls of hair follicle cycling. Physiol Rev. 2001; 81(1):449-494. DOI: 10.1152/physrev.2001.81.1.449. View

Onaolapo A, Adebayo A, Onaolapo O . Oral phenytoin protects against experimental cyclophosphamide-chemotherapy induced hair loss. Pathophysiology. 2017; 25(1):31-39. DOI: 10.1016/j.pathophys.2017.12.001. View

Hagiwara S, Uchida T, Koga H, Inomata M, Yoshizumi F, Moriyama M . The α-lipoic acid derivative sodium zinc dihydrolipoylhistidinate reduces chemotherapy-induced alopecia in a rat model: a pilot study. Surg Today. 2011; 41(5):693-7. DOI: 10.1007/s00595-010-4481-z. View

Paus R, Handjiski B, Eichmuller S, Czarnetzki B . Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. Am J Pathol. 1994; 144(4):719-34. PMC: 1887229. View

10.

Schilli M, Paus R, Menrad A . Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol-analogs. J Invest Dermatol. 1998; 111(4):598-604. DOI: 10.1046/j.1523-1747.1998.00350.x. View

11.

Yano K, Brown L, Detmar M . Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001; 107(4):409-17. PMC: 199257. DOI: 10.1172/JCI11317. View

12.

Muller-Rover S, Handjiski B, van der Veen C, Eichmuller S, Foitzik K, McKay I . A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol. 2001; 117(1):3-15. DOI: 10.1046/j.0022-202x.2001.01377.x. View

13.

Hendrix S, Handjiski B, Peters E, Paus R . A guide to assessing damage response pathways of the hair follicle: lessons from cyclophosphamide-induced alopecia in mice. J Invest Dermatol. 2005; 125(1):42-51. DOI: 10.1111/j.0022-202X.2005.23787.x. View

14.

COOK J, Haynes K, Werther G . Mitogenic effects of growth hormone in cultured human fibroblasts. Evidence for action via local insulin-like growth factor I production. J Clin Invest. 1988; 81(1):206-12. PMC: 442495. DOI: 10.1172/JCI113296. View

15.

Rudman S, Philpott M, Thomas G, Kealey T . The role of IGF-I in human skin and its appendages: morphogen as well as mitogen?. J Invest Dermatol. 1997; 109(6):770-7. DOI: 10.1111/1523-1747.ep12340934. View

16.

Philpott M, Sanders D, Kealey T . Effects of insulin and insulin-like growth factors on cultured human hair follicles: IGF-I at physiologic concentrations is an important regulator of hair follicle growth in vitro. J Invest Dermatol. 1994; 102(6):857-61. DOI: 10.1111/1523-1747.ep12382494. View

17.

Weger N, Schlake T . Igf-I signalling controls the hair growth cycle and the differentiation of hair shafts. J Invest Dermatol. 2005; 125(5):873-82. DOI: 10.1111/j.0022-202X.2005.23946.x. View

18.

Schlake T, Beibel M, Weger N, Boehm T . Major shifts in genomic activity accompany progression through different stages of the hair cycle. Gene Expr Patterns. 2004; 4(2):141-52. DOI: 10.1016/j.modgep.2003.09.009. View

19.

Wikramanayake T, Amini S, Simon J, Mauro L, Elgart G, Schachner L . A novel rat model for chemotherapy-induced alopecia. Clin Exp Dermatol. 2012; 37(3):284-9. PMC: 3305180. DOI: 10.1111/j.1365-2230.2011.04239.x. View

20.

Trueb R . Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009; 28(1):11-4. DOI: 10.1016/j.sder.2008.12.001. View